Meritage Portfolio Management Buys 8,806 Shares of Hologic, Inc. (NASDAQ:HOLX)

Meritage Portfolio Management boosted its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 6.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 141,485 shares of the medical equipment provider’s stock after acquiring an additional 8,806 shares during the quarter. Meritage Portfolio Management owned 0.06% of Hologic worth $10,109,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in HOLX. Nordea Investment Management AB lifted its holdings in Hologic by 4.5% during the third quarter. Nordea Investment Management AB now owns 1,616,999 shares of the medical equipment provider’s stock valued at $113,077,000 after purchasing an additional 69,494 shares in the last quarter. Louisiana State Employees Retirement System bought a new position in Hologic during the fourth quarter valued at $1,057,000. Pathstone Family Office LLC lifted its stake in shares of Hologic by 96.0% during the 3rd quarter. Pathstone Family Office LLC now owns 9,272 shares of the medical equipment provider’s stock worth $643,000 after acquiring an additional 4,542 shares during the last quarter. Ontario Teachers Pension Plan Board lifted its position in shares of Hologic by 186.7% during the third quarter. Ontario Teachers Pension Plan Board now owns 38,404 shares of the medical equipment provider’s stock worth $2,665,000 after purchasing an additional 25,010 shares during the last quarter. Finally, Livforsakringsbolaget Skandia Omsesidigt boosted its position in Hologic by 145.3% in the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 790 shares of the medical equipment provider’s stock valued at $56,000 after buying an additional 468 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on HOLX. William Blair reaffirmed an “outperform” rating on shares of Hologic in a research report on Friday, February 2nd. UBS Group raised their price objective on Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a report on Friday, February 2nd. Needham & Company LLC reaffirmed a “buy” rating and issued a $90.00 price target on shares of Hologic in a research note on Wednesday, April 10th. Raymond James upped their target price on shares of Hologic from $85.00 to $88.00 and gave the stock an “outperform” rating in a report on Friday, February 2nd. Finally, Evercore ISI lifted their price target on Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a report on Thursday, April 4th. Six analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $87.00.

Insider Activity

In related news, CFO Karleen Marie Oberton sold 14,940 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the sale, the chief financial officer now directly owns 103,916 shares in the company, valued at $7,793,700. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Hologic news, Director Charles J. Dockendorff sold 1,465 shares of the stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $76.21, for a total value of $111,647.65. Following the transaction, the director now directly owns 1,572 shares in the company, valued at $119,802.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Karleen Marie Oberton sold 14,940 shares of Hologic stock in a transaction on Monday, January 29th. The stock was sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the sale, the chief financial officer now owns 103,916 shares in the company, valued at $7,793,700. The disclosure for this sale can be found here. In the last quarter, insiders sold 32,846 shares of company stock worth $2,473,443. 1.75% of the stock is currently owned by company insiders.

Hologic Trading Up 1.0 %

Shares of HOLX traded up $0.75 during midday trading on Friday, hitting $76.46. 396,496 shares of the stock were exchanged, compared to its average volume of 1,762,392. The company has a debt-to-equity ratio of 0.55, a quick ratio of 3.18 and a current ratio of 3.89. The firm has a market cap of $17.95 billion, a P/E ratio of 36.26, a P/E/G ratio of 2.60 and a beta of 1.00. Hologic, Inc. has a 52-week low of $64.02 and a 52-week high of $87.88. The stock has a fifty day simple moving average of $75.98 and a 200 day simple moving average of $72.74.

Hologic (NASDAQ:HOLX) last released its earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.95 by $0.03. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $989.32 million. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The firm’s quarterly revenue was down 5.7% on a year-over-year basis. During the same period in the prior year, the business earned $1.07 EPS. On average, research analysts anticipate that Hologic, Inc. will post 4.01 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.